Skip to main content

Table 1 Baseline demographic characteristics and cardiovascular risk factors

From: Immune checkpoint inhibitors and the risk of major atherosclerotic cardiovascular events in patients with high-risk or advanced melanoma: a retrospective cohort study

Baseline

ICI treated (n = 289)

Non-ICI treated (n = 357)

p-value

Median age (years), IQR

67.9 (57.4—77.3)

66.1 (55.1—75.7)

0.09a

Male (%)

72.0

62.5

0.01b

Median BMI, IQR

27.7 (24.4—31.9)

27.2 (24.6—30.9)

0.41a

Current smoker (%)

11.7

13.0

0.66b

Ever smoker (%)

48.1

44.3

0.08b

Hypertension (%)

45.4

41.9

0.38b

Dyslipidemia (%)

26.3

26.4

0.98b

Diabetes (%)

12.1

12.4

0.92b

Past History of MACE (%)

9.8

13.5

0.15b

Aspirin usec (%)

17.4

15.6

0.53b

Statin usec (%)

30.0

27.5

0.49b

Median follow-up (months), IQR

23.2 (10.2 – 37.6)

23.4 (11.3 – 40.1)

0.69a

  1. aMann–Whitney U test
  2. bChi-squared test
  3. cDefined as documented aspirin or statin use at study baseline
  4. MACE Major atherosclerotic cardiovascular event